Wedbush Reiterates Rating on Damora Therapeutics, Inc. $DMRA

Written by Podchat · Published · Updated

Key Points

  • Wedbush now rates Damora Therapeutics, Inc. ($DMRA) "buy" with a $35 target.
  • Wedbush's $35 price target implies 69.99% upside from Damora Therapeutics, Inc.'s ($DMRA) current $20.59 share price.
  • The Street's average $DMRA price target is $44.67 (Strong Buy).
  • $DMRA last traded around $20.59.

Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.

Wedbush reiterated its rating on Damora Therapeutics, Inc. ($DMRA) to a "buy" rating in a recent research note and set a price target of $35, a 69.99% upside from the current price.

Damora Therapeutics, Inc. Stock Down 29.0%

Shares of Damora Therapeutics, Inc. ($DMRA) traded around $20.59 on Saturday, down 29.0% for the day.

Last price$20.59
Market cap$1.74B
Forward P/E-13.15
Beta1.48
52-week low$2.45
52-week high$38.33
50-day MA$29.18
200-day MA$25.99
Current ratio19.73
Quick ratio19.65

Damora Therapeutics, Inc. Earnings

EPS (ttm)-$0.26
Revenue (ttm)—
Net margin0%
Return on equity-99.74%
Next earningsNov 5, 2026

Analysts Set New Price Targets

ConsensusStrong Buy
Average target$44.67
High target$51
Low target$40
Analysts covering9

About Damora Therapeutics, Inc.

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.

ExchangeNasdaqCM
SectorHealthcare
IndustryBiotechnology
HeadquartersWaltham, MA
CEOMs. Jennifer A. Jarrett M.B.A.
Employees7
Websitehttps://www.damoratx.com

Get Damora Therapeutics, Inc. alerts

New 13F filings, insider trades, and analyst moves on $DMRA, sent to your inbox. Free, and you can unsubscribe anytime.

Related Filing Alerts

This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.